Meeting
2022 ASCO Annual Meeting
REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort.
Authors
Sophie Cousin
Early Phase Clinical Trials Unit and Thoracic Unit, Institut Bergonié, Bordeaux, France
Sophie Cousin , Jean Philippe Metges , Carine A. Bellera , Jean Philippe Guégan , Antoine Adenis , Carlos A. Gomez-Roca , Philippe Alexandre Cassier , Antoine Hollebecque , Coralie Cantarel , Lola Jade Palmieri , Michèle Kind , Isabelle Soubeyran , Jean Palussière , Alban Bessede , Antoine Italiano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03475953
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4060)
DOI
10.1200/JCO.2022.40.16_suppl.4060
Abstract #
4060
Poster Bd #
48
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.
First Author: Sophie Cousin
Poster
2020 ASCO Virtual Scientific Program
REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort.
First Author: Sophie Cousin
Poster
2018 Gastrointestinal Cancers Symposium
Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy.
First Author: Toshihiro Kudo
Poster
2023 ASCO Annual Meeting
A phase II study of regorafenib plus sintilimab as salvage-line treatments in non–MSI-H metastatic colorectal cancer (mCRC).
First Author: Rui Liu